Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration

NCT04270747 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04270747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04270747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
June 22, 2020
Completion date
January 30, 2023
Enrollment
576 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration (amd)